Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA developing proprietary therapeutics primarily for the treatment of central nervous system ("CNS") disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds.[3] In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni - a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.[2][4]

Titan Pharmaceuticals
TypePublic
Nasdaq: TTNP
IndustryPharmaceuticals
HeadquartersCalifornia
Key people
CCO Dane D. Hallberg [1]
RevenueIncrease $1.7 million [2]
Total assetsIncrease $8.4 million [2]
Number of employees
14 (Nov 2018)
Websitewww.titanpharm.com

Titan's principal asset is Probuphine,[5][6] a slow-release implant formulation of buprenorphine[7] for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016.[8] It was licensed to Braeburn Pharmaceuticals for marketing and commercialization.[6]

2018

As of its November 14th earnings call, Titan Pharmaceuticals is on track to commercialize its opioid addiction solution at a valuation between $75 and $100 million.[9]

References
  1. "Titan Strengthens Executive Leadership Team With Appointment Of Chief Commercial Officer". Titan Pharmaceuticals, Inc.
  2. "Titan Pharmaceuticals Reports Third Quarter 2018 Financial Results". Titan Pharmaceuticals, Inc.
  3. "Titan Pharma (TTNP) Prices $9.5M Public Offering".
  4. "Germany's Merck KGaA taking over Molteni Pharma of Italy - Pharmaceuti". www.thepharmaletter.com.
  5. "Technology". Titan Pharmaceuticals, Inc.
  6. "Annual Reports". Titan Pharmaceuticals, Inc.
  7. Solof, Barry (2013). The therapist's guide to addiction medicine a handbook for addiction counselors and therapists. New York: Central Recovery Press, LLC. p. 98. ISBN 9781937612443. Retrieved 21 September 2015.
  8. "Press Announcements - FDA approves first buprenorphine implant for treatment of opioid dependence". www.fda.gov. Retrieved 26 May 2016.
  9. "Titan Pharmaceuticals Third Quarter 2018 Financial Results". www.webcaster4.com.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.